Related Party Transactions	12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions As described in Note 12, in July 2021, the Company entered into the 2021 License Agreement with NHSc Pharma Partners (together with Société des Produits Nestlé S.A., “Nestlé”). NHSc Pharma Partners is an affiliate of two of the Company's significant stockholders, Société des Produits Nestlé S.A. and Nestlé Health Science U.S. Holdings, Inc. During the year ended December 31, 2021, the Company recognized $133,411 of related party revenue associated with the 2021 License Agreement. As of the year ended December 31, 2021, there was $6,089 of deferred revenue related to the 2021 License Agreement, which is classified as current or non-current in the consolidated balance sheets. As of December 31, 2021 there was $21,098 included in accrued expenses and other liabilities and $10,585 included in other long term liabilities related to the 2021 License Agreement. The Company has made no payments to Nestlé during the year ended December 31, 2021. There was no amount due from Nestlé as of December 31, 2021. As described in Note 12, in January 2016, the Company entered into the 2016 License Agreement with Société des Produits Nestlé S.A. (successor in interest to Nestec, Ltd.) for the development and commercialization of certain product candidates in development for the treatment and management of CDI and IBD, including UC and Crohn’s disease. Société des Produits Nestlé S.A. and its affiliate Nestlé Health Science U.S. Holdings, Inc. are two of the Company's significant stockholders. During the years ended December 31, 2021, 2020, and 2019, the Company recognized $10,446, $11,897, and $27,188, respectively, of related party revenue associated with the 2016 License Agreement. As of December 31, 2021 and 2020, there was $97,728 and $108,174, respectively, of deferred revenue related to the 2016 License Agreement, which is classified as current or non-current in the consolidated balance sheets. The Company has made no payments to Nestlé during the year ended December 31, 2021. There was no amount due from Nestlé as of December 31, 2021. In July 2019, the Company entered into a sublease agreement with Flagship Pioneering, one of the Company’s significant stockholders, to sublease a portion of its office and laboratory space in Cambridge, Massachusetts. The term of the sublease agreement commenced in July 2019 and ends on the last day of the 24th calendar month following commencement, with no option to extend (see Note 7). Under this agreement, the Company recorded other income of $1,575 and $1,813 during the year ended December 31, 2021 and 2020. The Company received cash payments of $1,575 and $1,813 during the year ended December 31, 2021 and 2020.

Related Party Transactions

12 Months Ended

Dec. 31, 2021

16.

Related Party Transactions

As described in Note 12, in July 2021, the Company entered into the 2021 License Agreement with NHSc Pharma Partners (together with Société des Produits Nestlé S.A., “Nestlé”). NHSc Pharma Partners is an affiliate of two of the Company's significant stockholders, Société des Produits Nestlé S.A. and Nestlé Health Science U.S. Holdings, Inc. During the year ended December 31, 2021, the Company recognized $133,411 of related party revenue associated with the 2021 License Agreement. As of the year ended December 31, 2021, there was $6,089 of deferred revenue related to the 2021 License Agreement, which is classified as current or non-current in the consolidated balance sheets. As of December 31, 2021 there was $21,098 included in accrued expenses and other liabilities and $10,585 included in other long term liabilities related to the 2021 License Agreement. The Company has made no payments to Nestlé during the year ended December 31, 2021. There was no amount due from Nestlé as of December 31, 2021.

As described in Note 12, in January 2016, the Company entered into the 2016 License Agreement with Société des Produits Nestlé S.A. (successor in interest to Nestec, Ltd.) for the development and commercialization of certain product candidates in development for the treatment and management of CDI and IBD, including UC and Crohn’s disease. Société des Produits Nestlé S.A. and its affiliate Nestlé Health Science U.S. Holdings, Inc. are two of the Company's significant stockholders. During the years ended December 31, 2021, 2020, and 2019, the Company recognized $10,446, $11,897, and $27,188, respectively, of related party revenue associated with the 2016 License Agreement. As of December 31, 2021 and 2020, there was $97,728 and $108,174, respectively, of deferred revenue related to the 2016 License Agreement, which is classified as current or non-current in the consolidated balance sheets. The Company has made no payments to Nestlé during the year ended December 31, 2021. There was no amount due from Nestlé as of December 31, 2021.

In July 2019, the Company entered into a sublease agreement with Flagship Pioneering, one of the Company’s significant stockholders, to sublease a portion of its office and laboratory space in Cambridge, Massachusetts. The term of the sublease agreement commenced in July 2019 and ends on the last day of the 24th calendar month following commencement, with no option to extend (see Note 7). Under this agreement, the Company recorded other income of $1,575 and $1,813 during the year ended December 31, 2021 and 2020. The Company received cash payments of $1,575 and $1,813 during the year ended December 31, 2021 and 2020.